PD50-07 SAFETY OF TESTOSTERONE THERAPY IN PATIENTS ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2016)

You have accessJournal of UrologySexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II1 Apr 2016PD50-07 SAFETY OF TESTOSTERONE THERAPY IN PATIENTS ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER Lawrence C. Jenkins, Rahul Krishnan, Boback M. Berookhim, Jonathan Coleman, James A. Eastham, Behfar Ehdaie, Vincent P. Laudone, Christian J. Nelson, and John P. Mulhall Lawrence C. JenkinsLawrence C. Jenkins More articles by this author , Rahul KrishnanRahul Krishnan More articles by this author , Boback M. BerookhimBoback M. Berookhim More articles by this author , Jonathan ColemanJonathan Coleman More articles by this author , James A. EasthamJames A. Eastham More articles by this author , Behfar EhdaieBehfar Ehdaie More articles by this author , Vincent P. LaudoneVincent P. Laudone More articles by this author , Christian J. NelsonChristian J. Nelson More articles by this author , and John P. MulhallJohn P. Mulhall More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2797AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Testosterone (T) therapy (TTH) has a contraindication on product labeling for use in men with prostate cancer. Over the past decade, with promotion of the saturation model, men who have been treated for prostate cancer, especially men with low-risk disease (clinically and pathologically) are being increasingly offered TTH. A small number of reports have presented data on the use of TTH in men on active surveillance (AS) for prostate cancer. We present here our data on TTH use in this population. METHODS We prospectively kept data on AS patients on TTH. Study population consisted of men who (i) were on AS for PCa (low volume cancer, Gleason sum ≤7, PSA ≤10) (ii) had two early morning total T levels (iii) were symptomatic or had abnormal bone densitometry (iv) elected to use TTH (v) had at least 6 months follow-up and (vi) agreed to intensive follow-up - total T (TT) and PSA levels every 3 months in year one after commencement of TTH. RESULTS 24 patients met all inclusion criteria. Mean age = 64.5±8.5 years. 22/24 (83%) patients had G6 cancer, 2/24 (17%) G7. Mean number of cores positive was 1.2±0.5 and mean core % positive was 11.7%±12.4. Comorbidities included hypertension 29%, diabetes 21%, hyperlipidemia 63%, CAD 13%, tobacco 13%. Mean duration in the AS program before commencing TTH = 17.6±19.6 months. Mean duration of follow-up while on TTH as an AS patient = 29.2±27.5 months. TTH was administered as follows: 17 (71%) transdermal, 2 (8%) intramuscular, 2 (8%) subcutaneous pellets, and 3 (13%) clomiphene citrate. Mean baseline TT level = 234±102 ng/dL and mean treatment TT level = 573±228 ng/dL. Mean pre-treatment PSA = 3.79±2.65 ng/mL and mean PSA (most recent) on treatment = 4.23±2.42 ng/mL. 8 (33%) had ≥1 point increase in PSA level. One patient stopped due to anxiety while 2 patients were upstaged (G6 to G7) while on TTH and proceeded to RP at 10.2 and 37.1 months after TTH commencement (0.11 and 1.56 point increases in PSA respectively). CONCLUSIONS Testosterone therapy in patients on active surveillance for prostate cancer is safe in a monitored treatment program and the conversion-to-intervention rate appears to be no higher than expected in the AS population not treated with TTH. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1188 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Lawrence C. Jenkins More articles by this author Rahul Krishnan More articles by this author Boback M. Berookhim More articles by this author Jonathan Coleman More articles by this author James A. Eastham More articles by this author Behfar Ehdaie More articles by this author Vincent P. Laudone More articles by this author Christian J. Nelson More articles by this author John P. Mulhall More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...